Grade My Investments
HomeFree Stock Grades › GILD

Gilead Sciences, Inc. (GILD) Stock Grade

GILD · Healthcare

A+
Grade updated: August 16, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$171.8B
P/E Ratio
17.9
Revenue Growth (YoY)
+2.4%
Net Margin
28.9%
Return on Equity
37.5%
Dividend Yield
2.7%

About Gilead Sciences, Inc.'s fundamentals

Gilead Sciences is a large-cap pharmaceutical company with a $152.7 billion market valuation and a P/E ratio of 17.9, indicating moderate valuation relative to its earnings. The company demonstrates strong profitability with a net margin of 28.9% and an impressive return on equity of 37.5%, showing efficient capital deployment. Revenue growth has been modest at 2.4% year-over-year, and the company returns capital to shareholders through a 2.6% dividend yield.

Track GILD free — no credit card required. Live grade + monthly AI report →